Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.50 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Neurocrine Biosciences Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 118.16 |
Open* | 117.45 |
1-Year Change* | -4.91% |
Day's Range* | 117.45 - 119.87 |
52 wk Range | 89.04-129.29 |
Average Volume (10 days) | 732.62K |
Average Volume (3 months) | 14.23M |
Market Cap | 10.77B |
P/E Ratio | 58.62 |
Shares Outstanding | 98.25M |
Revenue | 1.78B |
EPS | 1.87 |
Dividend (Yield %) | N/A |
Beta | 0.38 |
Next Earnings Date | Feb 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 5, 2023 | 118.16 | 2.47 | 2.14% | 115.69 | 118.61 | 114.89 |
Dec 4, 2023 | 116.09 | -0.15 | -0.13% | 116.24 | 117.55 | 115.36 |
Dec 1, 2023 | 116.63 | 0.12 | 0.10% | 116.51 | 117.70 | 115.44 |
Nov 30, 2023 | 116.48 | 3.49 | 3.09% | 112.99 | 116.91 | 112.99 |
Nov 29, 2023 | 113.11 | 2.23 | 2.01% | 110.88 | 114.05 | 110.86 |
Nov 28, 2023 | 112.34 | -0.03 | -0.03% | 112.37 | 112.95 | 111.62 |
Nov 27, 2023 | 112.85 | 1.48 | 1.33% | 111.37 | 113.10 | 110.34 |
Nov 24, 2023 | 112.00 | 1.80 | 1.63% | 110.20 | 112.19 | 110.20 |
Nov 22, 2023 | 110.55 | 0.99 | 0.90% | 109.56 | 111.70 | 109.56 |
Nov 21, 2023 | 109.26 | 1.50 | 1.39% | 107.76 | 110.90 | 107.75 |
Nov 20, 2023 | 109.31 | 1.96 | 1.83% | 107.35 | 109.94 | 107.35 |
Nov 17, 2023 | 108.56 | 0.63 | 0.58% | 107.93 | 109.55 | 107.88 |
Nov 16, 2023 | 108.23 | -1.38 | -1.26% | 109.61 | 109.87 | 107.60 |
Nov 15, 2023 | 110.31 | -1.65 | -1.47% | 111.96 | 112.72 | 110.20 |
Nov 14, 2023 | 112.16 | 1.31 | 1.18% | 110.85 | 114.44 | 110.85 |
Nov 13, 2023 | 109.80 | 3.76 | 3.55% | 106.04 | 110.27 | 105.81 |
Nov 10, 2023 | 106.76 | 0.43 | 0.40% | 106.33 | 108.11 | 102.85 |
Nov 9, 2023 | 112.06 | -2.90 | -2.52% | 114.96 | 115.17 | 111.54 |
Nov 8, 2023 | 114.94 | -1.31 | -1.13% | 116.25 | 117.29 | 114.43 |
Nov 7, 2023 | 116.36 | 2.39 | 2.10% | 113.97 | 117.24 | 113.15 |
Neurocrine Biosciences, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, February 5, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Neurocrine Biosciences Inc Earnings Release Q4 2023 Neurocrine Biosciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
Revenue | 1488.7 | 1133.5 | 1045.9 | 788.087 | 451.24 |
Total Operating Expense | 1309.7 | 1031 | 901.3 | 715.804 | 414.345 |
Selling/General/Admin. Expenses, Total | 751 | 583.3 | 433.3 | 354.062 | 248.932 |
Research & Development | 463.8 | 328.1 | 275 | 200.042 | 160.524 |
Operating Income | 179 | 102.5 | 144.6 | 72.283 | 36.895 |
Interest Income (Expense), Net Non-Operating | 34.9 | -1.1 | -37.9 | -25.741 | -15.054 |
Gain (Loss) on Sale of Assets | |||||
Other, Net | |||||
Net Income Before Taxes | 213.9 | 101.4 | 106.7 | 46.542 | 21.841 |
Net Income After Taxes | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Net Income Before Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Net Income | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Income Available to Common Excl. Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Income Available to Common Incl. Extra. Items | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Diluted Net Income | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Diluted Weighted Average Shares | 98.9 | 97.9 | 97.8 | 95.732 | 95.386 |
Diluted EPS Excluding Extraordinary Items | 1.56218 | 0.91522 | 4.16462 | 0.38662 | 0.22132 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 2.08583 | 1.86564 | 5.38021 | 1.66815 | 0.22132 |
Cost of Revenue, Total | 23.2 | 14.3 | 10.1 | 7.428 | 4.889 |
Gross Profit | 1465.5 | 1119.2 | 1035.8 | 780.659 | 446.351 |
Unusual Expense (Income) | 71.7 | 105.3 | 182.9 | 154.272 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
Revenue | 452.7 | 420.4 | 412 | 387.9 | 378.2 |
Cost of Revenue, Total | 11.5 | 8.5 | 7.7 | 6.1 | 4.8 |
Gross Profit | 441.2 | 411.9 | 404.3 | 381.8 | 373.4 |
Total Operating Expense | 379.1 | 534.6 | 308.6 | 300.1 | 393.5 |
Selling/General/Admin. Expenses, Total | 221.8 | 242.7 | 182.9 | 186.3 | 182.8 |
Research & Development | 145.8 | 139.5 | 118 | 107.7 | 135.9 |
Operating Income | 73.6 | -114.2 | 103.4 | 87.8 | -15.3 |
Interest Income (Expense), Net Non-Operating | 48 | 10.9 | 14.5 | 10.1 | -8 |
Net Income Before Taxes | 121.6 | -103.3 | 117.9 | 97.9 | -23.3 |
Net Income After Taxes | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Net Income Before Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Net Income | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Income Available to Common Excl. Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Income Available to Common Incl. Extra. Items | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Diluted Net Income | 95.5 | -76.6 | 89 | 68.5 | -16.9 |
Diluted Weighted Average Shares | 100.2 | 97.1 | 100.7 | 99 | 95.6 |
Diluted EPS Excluding Extraordinary Items | 0.95309 | -0.78888 | 0.88381 | 0.69192 | -0.17678 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.95309 | 0.17441 | 0.88381 | 0.69192 | 0.29916 |
Unusual Expense (Income) | 0 | 143.9 | 0 | 0 | 70 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1453.5 | 972.8 | 1016.2 | 831.034 | 737.777 |
Cash and Short Term Investments | 989.3 | 711.3 | 801 | 670.524 | 650.913 |
Cash & Equivalents | 262.9 | 340.8 | 187.1 | 112.279 | 141.714 |
Short Term Investments | 726.4 | 370.5 | 613.9 | 558.245 | 509.199 |
Other Current Assets, Total | 79.1 | 45.5 | 30.1 | 16.647 | 18.594 |
Total Assets | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
Property/Plant/Equipment, Total - Net | 145.6 | 155.8 | 127.4 | 116.278 | 33.869 |
Property/Plant/Equipment, Total - Gross | 211.9 | 207.7 | 169.1 | 149.837 | 62.14 |
Accumulated Depreciation, Total | -66.3 | -51.9 | -41.7 | -33.559 | -28.271 |
Long Term Investments | 401.5 | 624.4 | 265.3 | 355.522 | 216.028 |
Other Long Term Assets, Total | 330.9 | 319.5 | 325.8 | 3.206 | 5.477 |
Total Current Liabilities | 537.7 | 245.8 | 186.5 | 565.287 | 88.233 |
Accounts Payable | 46.214 | 38.381 | |||
Accrued Expenses | 129.3 | 99.5 | 81.4 | 72.719 | 34.41 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 408.807 | 0 |
Other Current Liabilities, Total | 3.3 | 3.5 | 7.5 | 37.547 | 15.442 |
Total Liabilities | 660.9 | 698.5 | 608.5 | 669.117 | 512.386 |
Total Long Term Debt | 0 | 335.1 | 317.9 | 0 | 388.496 |
Other Liabilities, Total | 123.2 | 117.6 | 104.1 | 103.83 | 35.657 |
Total Equity | 1707.8 | 1374 | 1126.2 | 636.923 | 480.765 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.1 | 0.1 | 0.1 | 0.092 | 0.091 |
Additional Paid-In Capital | 2122.4 | 2011.4 | 1849.7 | 1768.12 | 1660.36 |
Retained Earnings (Accumulated Deficit) | -406.8 | -635.8 | -725.4 | -1132.7 | -1177.76 |
Other Equity, Total | -7.9 | -1.7 | 1.8 | 1.413 | -1.932 |
Total Liabilities & Shareholders’ Equity | 2368.7 | 2072.5 | 1734.7 | 1306.04 | 993.151 |
Total Common Shares Outstanding | 96.5 | 94.9 | 93.5 | 92.272 | 90.797 |
Total Receivables, Net | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
Accounts Receivable - Trade, Net | 350 | 185.5 | 157.1 | 126.575 | 57.406 |
Long Term Debt | 0 | 335.1 | 317.9 | 0 | 388.496 |
Total Inventory | 35.1 | 30.5 | 28 | 17.288 | 10.864 |
Payable/Accrued | 235.7 | 142.8 | 97.6 | ||
Intangibles, Net | 37.2 | ||||
Current Port. of LT Debt/Capital Leases | 169.4 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1649.9 | 1496.6 | 1432.8 | 1453.5 | 1205.5 |
Cash and Short Term Investments | 1095.1 | 976.7 | 894.6 | 989.3 | 799.4 |
Cash & Equivalents | 293.7 | 160.2 | 103.8 | 262.9 | 212.2 |
Short Term Investments | 801.4 | 816.5 | 790.8 | 726.4 | 587.2 |
Total Receivables, Net | 417.8 | 387.6 | 391.6 | 350 | 301.2 |
Accounts Receivable - Trade, Net | 417.8 | 387.6 | 391.6 | 350 | 301.2 |
Total Inventory | 28.8 | 31.7 | 33.4 | 35.1 | 37 |
Other Current Assets, Total | 108.2 | 100.6 | 113.2 | 79.1 | 67.9 |
Total Assets | 2848.2 | 2613.1 | 2359.8 | 2368.7 | 2143.4 |
Property/Plant/Equipment, Total - Net | 149.6 | 149.1 | 147.2 | 145.6 | 150.5 |
Long Term Investments | 587.5 | 515.6 | 380.3 | 401.5 | 457.5 |
Other Long Term Assets, Total | 426.3 | 414.9 | 362.3 | 330.9 | 329.9 |
Total Current Liabilities | 691.6 | 582.5 | 374.1 | 537.7 | 485.1 |
Payable/Accrued | 394.9 | 391.6 | 355.7 | 347.6 | 297.8 |
Accrued Expenses | 125.9 | 17.7 | 17.6 | 17.4 | 17.3 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.9 | 3.5 | 0.8 | 3.3 | 0.8 |
Total Liabilities | 846.1 | 760.1 | 675.3 | 660.9 | 598.8 |
Total Long Term Debt | 0 | 0 | 169.5 | 0 | 0 |
Long Term Debt | 169.5 | 0 | 0 | ||
Other Liabilities, Total | 154.5 | 177.6 | 131.7 | 123.2 | 113.7 |
Total Equity | 2002.1 | 1853 | 1684.5 | 1707.8 | 1544.6 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 2308.5 | 2241.9 | 2170.5 | 2122.4 | 2054.3 |
Retained Earnings (Accumulated Deficit) | -304.8 | -387.9 | -483.4 | -406.8 | -495.8 |
Other Equity, Total | -1.7 | -1.1 | -2.7 | -7.9 | -14 |
Total Liabilities & Shareholders’ Equity | 2848.2 | 2613.1 | 2359.8 | 2368.7 | 2143.4 |
Total Common Shares Outstanding | 98.2 | 97.6 | 97.5 | 96.5 | 96.1 |
Current Port. of LT Debt/Capital Leases | 169.9 | 169.7 | 0 | 169.4 | 169.2 |
Intangibles, Net | 34.9 | 36.9 | 37.2 | 37.2 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 154.5 | 89.6 | 407.3 | 37.012 | 21.111 |
Cash From Operating Activities | 339.4 | 256.5 | 228.5 | 152.054 | 101.364 |
Cash From Operating Activities | 15.1 | 10.9 | 8.6 | 7.452 | 4.024 |
Non-Cash Items | 217.6 | 135 | 161.2 | 107.349 | 77.986 |
Cash Interest Paid | 6.6 | 8.6 | 11.6 | 11.644 | 11.644 |
Changes in Working Capital | -67.4 | 16.7 | -37.9 | 0.241 | -1.757 |
Cash From Investing Activities | -177.1 | -130.2 | 4.1 | -211.073 | -242.915 |
Capital Expenditures | -16.5 | -23.4 | -10.9 | -14.748 | -24.812 |
Other Investing Cash Flow Items, Total | -160.6 | -106.8 | 15 | -196.325 | -218.103 |
Cash From Financing Activities | -234.3 | 27.4 | -157.8 | 27.313 | 29.53 |
Issuance (Retirement) of Stock, Net | 44.7 | 27.5 | 29.1 | 27.313 | 29.53 |
Issuance (Retirement) of Debt, Net | -279 | -0.1 | -186.9 | 0 | 0 |
Net Change in Cash | -73.3 | 153.7 | 74.8 | -31.706 | -112.021 |
Cash Taxes Paid | 14.4 | 5.1 | 15.3 | 0.507 | |
Deferred Taxes | 19.1 | 4.3 | -310.7 | ||
Amortization | 0.5 | ||||
Foreign Exchange Effects | -1.3 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -76.6 | 154.5 | 65.5 | -3 | 13.9 |
Cash From Operating Activities | -125.2 | 339.4 | 196.4 | 97.6 | -40.5 |
Cash From Operating Activities | 4.1 | 15.1 | 11.2 | 7.2 | 3.3 |
Deferred Taxes | -31.6 | 19.1 | 5.6 | -3.4 | -0.3 |
Non-Cash Items | 35.5 | 217.6 | 180 | 147.1 | 18.3 |
Changes in Working Capital | -57.5 | -67.4 | -65.9 | -50.3 | -75.7 |
Cash From Investing Activities | -42.1 | -177.1 | -61.5 | -0.2 | -31.6 |
Capital Expenditures | -8.5 | -16.5 | -14.7 | -16.4 | -7.6 |
Other Investing Cash Flow Items, Total | -33.6 | -160.6 | -46.8 | 16.2 | -24 |
Cash From Financing Activities | 8.2 | -234.3 | -258.9 | -270.3 | 6.1 |
Issuance (Retirement) of Stock, Net | 8.2 | 44.7 | 20.1 | 8.7 | 6.1 |
Issuance (Retirement) of Debt, Net | -279 | -279 | -279 | 0 | |
Net Change in Cash | -159.1 | -73.3 | -124 | -172.9 | -66 |
Cash Taxes Paid | 0.2 | 14.4 | 4.3 | 3.1 | |
Cash Interest Paid | 6.6 | 4.6 | 4.6 | ||
Amortization | 0.9 | 0.5 | |||
Foreign Exchange Effects | -1.3 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.6161 | 10366912 | 220306 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.76 | 9530883 | -26814 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.0516 | 3956499 | 156584 | 2023-06-30 | LOW |
Bellevue Asset Management AG | Investment Advisor | 2.6756 | 2612800 | -500 | 2023-06-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.9547 | 1908844 | -85677 | 2023-06-30 | LOW |
Armistice Capital LLC | Hedge Fund | 1.6897 | 1650000 | 58000 | 2023-06-30 | MED |
Renaissance Technologies LLC | Hedge Fund | 1.6829 | 1643402 | -303662 | 2023-06-30 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.6353 | 1596880 | -54369 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.56 | 1523408 | 87671 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.4331 | 1399439 | 228393 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.3377 | 1306273 | 831881 | 2023-06-30 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.3103 | 1279500 | 69400 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.2666 | 1236839 | -61520 | 2023-06-30 | LOW |
Deerfield Management Company, L.P. | Hedge Fund | 1.2388 | 1209714 | -535000 | 2023-06-30 | MED |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 1.2186 | 1190026 | -30338 | 2023-06-30 | LOW |
Woodline Partners LP | Hedge Fund | 1.1799 | 1152189 | 753495 | 2023-06-30 | HIGH |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1308 | 1104267 | 242362 | 2023-06-30 | LOW |
Brown Advisory | Investment Advisor/Hedge Fund | 1.1158 | 1089582 | -10274 | 2023-09-30 | LOW |
DSM Capital Partners, LLC | Investment Advisor | 1.0858 | 1060270 | -199261 | 2023-06-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.016 | 992153 | -119041 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com